Cure8 research brief
Why This Matters
AHR signaling may influence epithelial inflammation in IBD and could be a potential target for future therapies or biomarker research. Findings are preliminary but point to IL‑8 as a responsive inflammatory mediator in these cell models.
Who Should Pay Attention
Researchers studying immune pathways, biomarkers, or drug discovery for IBD; clinicians interested in emerging basic-science mechanisms underlying intestinal inflammation.
Study Snapshot
What To Know
This study used in vitro intestinal epithelial and co-culture models to test whether blocking the aryl hydrocarbon receptor (AHR) alters inflammatory signaling. The authors compared two models and selected a TNF‑α/LPS–stimulated Caco-2 epithelial model for experiments.
Pharmacologic AHR inhibition with BAY2416964 reduced expression of the AHR target TIPARP and lowered IL‑8 mRNA; reductions in IL‑8 protein and other cytokines (IL‑6, TNF‑α) were smaller and did not reach statistical significance.
The work provides functional lab evidence that AHR can modulate epithelial inflammatory responses, with IL‑8 showing the most consistent change when AHR is inhibited in these models.
The authors note limits of the models and call for complementary approaches and more physiologically relevant systems to define the broader significance of AHR inhibition in intestinal inflammation.
This report is an in vitro/basic-science study — it does not test treatments in animals or people and does not provide clinical efficacy or safety information about AHR inhibitors for IBD.
Keep In Mind
This is an in vitro study using Caco-2 cell models; results do not demonstrate clinical benefit. BAY2416964 effects on protein levels were modest and not statistically significant for some measures. Further work in more complex models and in vivo systems is needed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The study was approved by the Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.CHMC.REC.1401.125). No human participants or animals were involved in the experiments reported in this study. Consent for publication: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.